Guangdong, China

Dongsheng Dai


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
2 patents (USPTO):

Title: The Innovations of Inventor Dongsheng Dai

Introduction

Dongsheng Dai is a prominent inventor based in Guangdong, China, recognized for his groundbreaking contributions in the fields of immunology and molecular biology. With a total of two patents to his name, Dai's work focuses on developing advanced therapeutic solutions aimed at addressing cardiovascular diseases.

Latest Patents

Dai’s latest patents revolve around the development of nucleic acids encoding anti-PCSK9 antibodies. These inventions detail a monoclonal antibody that specifically binds to PCSK9, a protein that plays a crucial role in cholesterol metabolism. The pharmaceutical compositions and methods related to these antibodies are designed to block the interaction between PCSK9 and LDL receptors (LDLR). By upregulating the presence of LDLR on cell surfaces, these innovations aim to enhance the metabolism of LDL cholesterol and triglycerides, subsequently preventing or treating cardiovascular diseases associated with hypercholesterolemia.

Career Highlights

Dongsheng Dai’s career is marked by his dedication to discovering novel therapeutic agents that can significantly impact public health. His expertise in immunology and molecular biology has allowed him to push the boundaries of current medical treatments, particularly in combating high cholesterol levels and related cardiovascular conditions.

Collaborations

Throughout his career, Dai has collaborated with notable professionals in the field, including Baiyong Li and Zhongmin Maxwell Wang. These partnerships have fostered a collaborative environment conducive to innovation and technological advancement within the pharmaceutical sector.

Conclusion

Dongsheng Dai exemplifies the spirit of innovation in medical science. His contributions, particularly in the development of anti-PCSK9 antibodies, hold great promise for enhancing the treatment of cardiovascular diseases. As he continues to work with Ad Pharmaceutical Co., Inc., his ongoing research may further reshape the landscape of therapeutic options available for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…